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S206 Oral Presentationswithout deletion 17p appear to also have shorter time to relapse,
more follow up is needed. Further investigation of risk stratification
of MCL patients according to cytogenetic subgroup is warranted.
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MAINTAINED HEMATOLOGIC AND ORGAN RESPONSES FOLLOWING RISK
ADAPTED STEM CELL TRANSPLANT (SCT) IN SYSTEMIC LIGHT-CHAIN
AMYLOIDOSIS (AL) USING BORTEZOMIB AND DEXAMETHASONE AS
CONSOLIDATION THERAPY
Landau, H.J.1, Hassoun, H.1, Rosenzweig, M.A.2, Bello, C.1, Hoover, E.1,
Riedel, E.1, Comenzo, R.L.3 1Memorial Sloan-Kettering Cancer Center,
New York, NY; 2City of Hope Cancer Center, Duarte, CA; 3TuftsMedical
Center, Boston, MA
Background:Risk-adaptedMELdosing has improved the safety but
may also compromise the efficacy of SCT for pts with AL.We report
results of a phase II trial using bortezomib and dexamethasone (BD)
as consolidation following risk-adapted SCT for pts with AL.
Methods:Newly diagnosed pts with AL involving # 2 organs were
assignedMEL 100, 140 or 200mg/m2 with SCT, based on age, renal
function and cardiac involvement. Response was assessed at 2-3, 12,
and 24 mos post-SCT. Pts with persistent clonal plasma cell disease
at 2-3 mos post-SCT received consolidation with BD for up to 6 cy-
cles. Organ response and overall survival (OS) were assessed at 12
and 24 mos post-SCT.
Results: 41 pts with kidney (71%), heart (46%), liver/GI (12%) and
peripheral nervous system (12%) disease were enrolled; 44% had 2
organ-involvement. One pt was ineligible; 1 is within 100 days of
SCT. Four pts with advanced cardiac AL died within 100 days of
SCT, resulting in 10% (4/40) TRM. With median follow-up 39
mos, OS at 12 mos post-SCT was 88%. In pts with heart involve-
ment OS was 74% and 58% at 12 and 24 mos respectively, versus
100% at both time points in those without cardiac AL (P 5 0003).
Increased BNP and troponin were associated with worse OS, HR
1.3 (P 5 0.0001) and HR 3.9 (P 5 0.0003), respectively. Post-
SCT, the hematologic RR was 54% with 28% pts achieving CR.
For persistent clonal disease, 65% (22/34) received BD. Among all
pts evaluable at 12 mos post-SCT, the hematologic RR was 96%
(26/27) with 67% CR; 1 pt progressed. At 24 mos post-SCT the
RR was 84% (16/19) including 50% who maintained CR; 3 more
pts progressed. Of pts who received BD, 89% had an improved he-
matologic response; all responded after 1 cycle. Organ responses
evolved over time and were seen in 56% and 88% of pts at 12 and
24 mos post-SCT, respectively. In pts with renal AL, 45% (9/20)
achieved an organ response at 12 mos which increased to 92% (12/
13) by 24 mos. No pt had worsening organ function.
Conclusions: In newly diagnosed AL pts, BD following risk-adapt-
ed SCT is effective for eradicating persistent clonal disease. Hema-
tologic responses are rapid resulting in high overall and
unprecedented CR rates. Organ function improves in the majority
of patients, over time. Cardiac disease is associated with inferior
OS and cardiac biomarkers are useful for assigning risk. Relapses oc-
cur after completion of therapy and a maintenance regimen follow-
ing post-SCT consolidation is worthy of further study.
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GEMCITABINE, BUSULFAN AND MELPHALAN (Gem/Bu/Mel) IS A NEW
HIGH-DOSE CHEMOTHERAPY (HDC) REGIMEN WITH HIGH ACTIVITY
IN REFRACTORY OR POOR-RISK RELAPSED NON-HODGKIN’S LYM-
PHOMA (NHL) PATIENTS RECEIVING AN AUTOLOGOUS STEM-CELL
TRANSPLANT (ASCT)
Nieto, Y.1, Jones, R.B.1, Popat, U.1, Andersson, B.1, Valdez, B.1,
Thall, P.2, Shpall, E.J.1, Chancoco, C.1, Alousi, A.1, Anderlini, P.1,
Hosing, C.1, Qazilbash, M.1, Bashir, Q.1, Kebriaei, P.1, Khoui, I.1,
Ciurea, S.1, Parmar, S.1, Rondon, G.1, Champlin, R.1 1UT MD Ander-
son Cancer Center, Houston, TX; 2UT MD Anderson Cancer Center,
Houston, TX
Background: BEAM is considered a standard HDC regimen for
ASCT for NHL. However, pts with primary refractory tumors (fail-
ure to achieve a CR to 1st-line treatment) or high-risk relapse have
poor outcomes after BEAM or similar regimens, underscoring the
need for more active HDC combinations.Methods:We developed a new HDC regimen combining gemcita-
bine (Gem) with busulfan (Bu) and melphalan (Mel) (Gem/Bu/Mel)
pursuing DNA damage repair inhibition. Gem was infused at a fixed
rate of 10 mg/m2/min (optimizing its intracellular activation) x 2
(days -8 and -3), immediately preceding the first doses of Bu and
Mel. Bu was given as 4 daily doses (d-8 to -5) targeting AUC
4,000/d. Mel was given at 60 mg/m2/d (d-3 and -2). Gem dose was
escalated by extending its infusion in sequential cohorts. Pts with
CD20+ tumors received rituximab at 375 mg/m2 (d+1 and +8).
This trial was open to pts with refractory lymphoid tumors. NHL
pts with primary refractory disease, CR1 \12 months or .1 re-
lapse/PD were eligible.
Results:GemMTDwas identified as an infusion length of 4.5 hours
(total dose 2,550 mg/m2/d), causing manageable mucositis and rash.
In this study we included 46 NHL pts: 30 B-LCL (16 primary
DLCL, 2 double-hit myc+/BCL2+ LCL, 4 transformed, 4 primary
mediastinal, 4 primary CNS), 3 Burkitt’s, 2 follicular, 11 T-NHL
(6 anaplastic, 2 PTCL, 2 NK/T, 1 angioimmunoblastic). Median
age 53 (26-66), median 3 (2-9) prior regimens (prior Gem in 6), prior
radiotherapy 10 pts. Primary refractory and poor-risk relapsed dis-
ease in 22 and 24 pts, respectively. Other prognostic features in-
cluded: 1) No. prior relapses: 1: N 5 17, .1: N 5 29; 2) IPI at
relapse/PD: 0-1: 7 pts, .1: 33 pts (.3: 8 pts), N/A: 6 pts; 3) high
LDH at relapse/PD: 13 pts; 4) PET negative at HDC: 23 pts,
PET positive: 23 pts (11 of these in PD at ASCT).
The CR and overall RR were: 1) B-LCL: 69% and 100%; T-
NHL: 66% and 66%; Burkitt’s and follicular: all pts had a CR. All
6 pts with prior gemcitabine (none of whom had responded to it)
had a CR toGem/Bu/Mel. At median follow-up of 16 (2-57)months,
the EFS and OS rates are: 1) B-LCL: 80% and 83%, respectively; 2)
T-NHL: both 73%; 3) Burkitt’s: all 3 pts relapsed at 3 months and
died; 4) Follicular: 1 pt alive in CR, 1 pt alive in relapse.
Conclusions: Our preliminary results in refractory or poor-risk re-
lapsed NHL suggest high activity of Gem/Bu/Mel, particularly in
the B-LCL and T-cell histologies. Disease-specific phase 2 trials
are warranted.
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COMPARISON OF GEMCITABINE, BUSULFAN ANDMELPHALAN (Gem/Bu/
Mel) WITH BEAM AND BUSULFAN/MELPHALAN (Bu/Mel) IN CONCUR-
RENT COHORTS OF REFRACTORY HODGKIN’S LYMPHOMA (HL)
PATIENTS RECEIVING AN AUTOLOGOUS STEM-CELL TRANSPLANT
Nieto, Y.1, Jones, R.B.1, Liu, P.2, Anderlini, P.1, Popat, U.1,
Andersson, B.1, Shpall, E.J.1, Alousi, A.1, Hosing, C.1, Kebriaei, P.1,
Qazilbash, M.1, Frazier, E.1, Chancoco, C.1, Bashir, Q.1, Ciurea, S.1,
Parmar, S.1, Champlin, R.1 1UTMDAnderson Cancer Center, Houston,
TX; 2UT MD Anderson Cancer Center, Houston, TX
Background: BEAM is considered a standard HDC regimen for pts
with Hodgkin’s lymphoma (HL) who are candidates for an ASCT.
However, pts with primary refractory tumors or high-risk relapse
have poor outcomes after BEAM, underscoring the need for more
active HDC combinations.
Methods:We have developed a new HDC regimen of gemcitabine
(Gem), busulfan (Bu) and melphalan (Mel) (Gem/Bu/Mel), exploit-
ing their synergy based on DNA damage repair inhibition. At its
MTD, Gem was infused at a fixed dose rate of 10 mg/m2/min (opti-
mizing its intracellular activation) over 4.5 hours (d-8 and -3) (total
dose 5,550 mg/m2), preceding the first doses of Bu or Mel. Bu was
given as 4 daily doses (d-8 to -5) targeting AUC 4,000/d x4. Mel
was given at 60 mg/m2/d x2 (d-3 and -2). We compared the subset
of refractory HL pts of this study with all other refractory HL pts
transplanted during the same period at our institution, who were el-
igible for this trial but either received BEAMoff protocol or were en-
rolled in a separate trial of Bu/Mel. All of them met $1 of the
following criteria: primary induction failure (PIF) (\CR to 1st line
chemotherapy), CR1\6 mo, or .1 relapse. Pts with relapsed and
non-refractory HL were excluded from this analysis.
Results:We analyzed 209 pts in these cohorts: 1) Gem/Bu/Mel (N
5 89) (Jan 07-June 11), median f/u: 16 (3-57)mo; 2) BEAM (N5 83)
(Jan 05-Aug 11), median f/u: 17 (2-56) mo; 3) Bu/Mel (N5 37) (Apr
05-Dec 07), median f/u: 36 (17-56) mo. The Gem/Bu/Mel cohort
had substantially higher % PIF, .1 relapses, bulky tumors (.5
cm) at relapse/PD, extranodal disease at relapse/PD, PET+ tumors
at HDC and PD at HDC.
